Innate Pharma regains rights on CD123 targeting ANKET® and announces Sanofi’s intention to make a strategic investment in the Company April 30, 2025
Sarah Cannon Research Institute at Colorado Blood Cancer Institute Announced as Key Clinical Trial Site for Ph 1 Trial of CER-1236 in AML April 30, 2025
NDA submitted to the US FDA for ziftomenib in adult patients with R/R AML with NPM 1 mutation April 16, 2025
RAINIER Trial Data Update: Two Additional AML Patients Achieve Remission Within 30 Days of Treatment March 26, 2025
Actimab-A + CLAG-M Trial Results in Patients with R/R AML published in the Journal Leukemia March 18, 2025
Frontline Triple Drug Therapy with Tuspetinib Achieves Notable Responses in Newly Diagnosed AML Patients in Ph 1/2 TUSCANY Trial February 19, 2025
Positive FDA Guidance Received for Acceleration of Registration-Enabling MIRACLE Trial for R/R AML February 19, 2025
Positive Ziftomenib Monotherapy Registrational Trial and Positive FDA Feedback for Upcoming Frontline Combination Trial Designs Announced February 11, 2025
FAILED TRIAL: Ph 3 Bridging Trial in China in Patients with R/R AML did not demonstrate favorable benefit for uproleselan December 26, 2024
